TTF小组/TTF疗法的发展历程/Tumour treating fields therapy for glioblastoma: current advances and future directions：修订间差异
（Edit summary） |
（Edit summary） |
||
| 第1行： | 第1行： | ||
{{文章推荐|Reason=比较全面地介绍了TTF疗法近20年的发展历史，包括其机制研究、临床研究、现实应用等多方面的情况|Journal=British Journal of Cancer |PubYear=2020|DOI=10.1038/s41416-020-01136-5|Category_=综述|Domain=TTF疗法的发展历程|RecomBy=杨鑫|RecomGrp=TTF小组|ReviewBy=胡春华|Abstract=Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.|DetaialsDM=综述|Citation_=183}} | {{文章推荐|Reason=比较全面地介绍了TTF疗法近20年的发展历史，包括其机制研究、临床研究、现实应用等多方面的情况|Journal=British Journal of Cancer |PubYear=2020|DOI=10.1038/s41416-020-01136-5|Category_=综述|Domain=TTF疗法的发展历程|RecomBy=杨鑫|RecomGrp=TTF小组|ReviewBy=胡春华|Abstract=Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.|DetaialsDM=综述|Citation_=183|CitationBy=/scholar?cites=521581140614565860&as_sdt=2005&sciodt=0,5&hl=en}} | ||
2024年1月22日 (一) 14:11的最新版本
推荐理由
比较全面地介绍了TTF疗法近20年的发展历史，包括其机制研究、临床研究、现实应用等多方面的情况
| 文章简介 | |
|---|---|
| 期刊 | British Journal of Cancer |
| 发表年份 | 2020 |
| DOI | 10.1038/s41416-020-01136-5 |
| 类型 | 综述 |
| 领域 | TTF疗法的发展历程 |
| 引用量 | 183 |
| 推荐信息 | |
|---|---|
| 推荐人 | 杨鑫 |
| 审核 | 胡春华 |
| 推荐小组 | TTF小组 |
摘要
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.
细分领域
< | 综述